MR imaging and 18F-FDG PET/CT play central and complementary roles in the care of patients with gynecologic cancer. Because treatment often requires combinations of surgery, radiotherapy, and chemotherapy, imaging is central to triage and to determining prognosis. This article reviews the use of the 2 imaging modalities in the initial evaluation of 3 common cancers: uterine cervical, uterine endometrial, and epithelial ovarian. Imaging features that affect management are highlighted, as well as the relative strengths and weaknesses of the 2 modalities. Use of imaging after initial therapy to assess for recurrence and to plan salvage therapy is described. Newer functional and molecular techniques in MR imaging and PET are evaluated. Finally, we describe our initial experience with PET/MR imaging, an emerging technology that may prove to be a mainstay in personalized gynecologic cancer care.
- 6α-<sup>18</sup>F-fluoro-17β-estradiol PET
- Cu-labeled diacetyl-bis (N4-methylthiosemicarbazone) PET
- Diffusion weighted imaging
- Dynamic contrast enhanced MRI
- Perfusion MRI
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging